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ABSTRACT 
Objectives
Annual completion of a Valproate Risk Acknowledgement Form (RAF) is mandated in the United Kingdom 
due to neurodevelopmental risks of in utero valproate exposure. The number of women of childbearing 
potential taking valproate, the uptake of the RAF within this population and their clinical outcomes is not 
known or monitored. The aim of this study surveyed responses of clinicians administering the RAF to 
women of childbearing potential taking valproate medications.
Materials and Methods
• Study design - national online survey distributed to clinical specialists throughout the United Kingdom 
via their national organisations. 
• Participants - clinicians qualified to counsel and administer the valproate RAF (as defined by the 
Medicines and Healthcare products Regulatory Agency).
• Main outcome measures – quantitative and qualitative responses regarding identification, uptake, 
effects and reactions to the RAF. 
• Trial registration – registered at the Clinical Governance and Audit Committee at Royal Free London NHS 
Foundation Trust Hospital.
Results
215 respondents covering more than 4775 patient encounters were captured. Most patients continued on 
valproate, 90% with epilepsy as the indication. Respondents reported that seizure control deteriorated 
when switched to levetiracetam (33%) and lamotrigine (43%), compared to 7% when continuing valproate 
(P<.001).
Conclusions
33-43% of clinicians reported seizure control deterioration in women changed to alternatives to 
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capture of data automated through online RAFs and linked to patient outcomes is needed. There remains 
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INTRODUCTION
Valproate medications (valproic acid, sodium valproate, divalproex sodium and related compounds, trade 
names include Epilim and Depakote) are licenced for use in epilepsy, bipolar disorder and in some 
countries for migraine. They are the most effective treatment for idiopathic generalised epilepsies 
(genetic generalised epilepsies).[1,2] There are increasing restrictions of its use in many countries including 
United Kingdom (UK) because of concerns about teratogenicity and developmental problems in offspring 
exposed to valproate estimated at 10% and 40% respectively.[3] In the UK since 2018 the Medicines and 
Healthcare products Regulatory Agency (MHRA) mandate the completion of a valproate risk 
acknowledgement form (RAF) by an appropriate specialist in all females of childbearing potential who are 
taking valproate.[4] There are no studies evaluating implementation challenges, the uptake of this 
initiative and the views of patients and clinicians using the form.[5-7] The impact of changing from 
valproate to other medications, or avoiding valproate in females, has not been systematically assessed. 
This project surveyed clinicians responsible for identifying, reviewing, and counselling relevant patients, 
and administering the RAF.
MATERIALS and METHODS
The survey was drafted by two of the authors (HAL and MMM) taking into account key topic areas. It 
incorporated multiple choice and free text responses, there were 35 questions and it took 10-15 minutes 
to complete (online Appendix https://forms.gle/FQGRDBDCw2hLcMKq6). It was reviewed and modified 
by other authors and the Epilepsy Advisory Group of the Association of British Neurologists. Clinical 
diagnoses were defined as those ascribed by the responding clinicians. The Clinical Governance and Audit 
Committee at The Royal Free London NHS Foundation Trust Hospital approved and registered it. 
Distribution was through newsletters and websites of the Association of British Neurologists, the Epilepsy 
Specialist Nurse Association Intellectual Disability section of the Royal College of Psychiatry and the British 
Paediatric Neurology Association. The population were clinical professionals where consent was implicit 
by completing the questionnaire as confirmed by current guidelines.[8] The anonymous survey was carried 
out on Google Drive between April to July 2019. Data Handling was in accord with the Data Protection Act 
of 2018, incorporating General Data Protection Regulation guidance.[9] 
Data Analysis 
Descriptive and graphical analysis of data collected was performed to summarise key quantitative 
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analysis into type of specialist and indication for valproate use was avoided because the numbers in some 
groups were too small for this to be meaningful. Qualitative data was analysed thematically following the 
steps outlined by Braun and Clarke.[10] 
Patient Involvement
Requests from two patients gave the impetus to the study, and specific questions about the pregnancy 




The survey was completed by 215 specialist clinicians responsible for the prescription of valproate and/or 
completion of the MHRA risk acknowledgement form (RAF) for women of childbearing potential (WCP). 
They were consultant neurologists (119/215 55.3%; one third with special interest in epilepsy), consultant 
psychiatrists (48/215, 22.3%; half with intellectual disability special interest), consultant paediatricians 
(22/215, 10.2%), specialty doctors (9/215, 3.3%), epilepsy clinical nurse specialists (14/215, 6.5%), and 
general practitioners (3/215, 1.4%) with an average of 18 years experience prescribing sodium valproate 
(range 0-40 years; n=215).
Identification of Women of Childbearing Potential taking Valproate
Surveyed clinicians identified or estimated they had collectively completed a total of 4775 RAFs for 
women of childbearing potential taking or going to start valproate. Seven percent (16/215) of responders 
were unable to provide any estimate. 
Healthcare professionals had identified relevant individuals using a range of methodologies: one third 
used clinic appointments alone (32.6%); record searches (17.2%) and pharmacy searches (1.9%) were 
used less frequently in isolation. 100 responders (46.5%) used a combination of identification methods, 
(Figure 1A). 
87% (n=186) specified epilepsy as the diagnostic indication for valproate;  this was further categorised 
into “epilepsy only” (67%), “epilepsy + intellectual disability” (24.2%), “epilepsy + bipolar disorder” 
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was an indication in nine respondents (4.2%), bipolar disorder in 28 (13%), and other mood disorders in 
22 (10.2%), (Supplemental Figure 1).
Completion of Risk Acknowledgement Form in WCP taking Valproate
42.8% of respondents (n=92) stated that “all” WCP taking valproate under their practice had a completed 
RAF in accordance with MHRA 2018 regulations; 30.7% stated “most” (n=66), 7.9% “about half” (n=17) 
and 7% “minority” (n=15). 6% (n=13) of clinicians responded “none”, and 6% percent were “unsure” 
whether WCP taking valproate in their practice had been reviewed and had a RAF completed, (Figure 1B).
Outcomes Following Completion of RAF in WCP without ID taking Valproate  
68.5% (n=137) of clinicians continued valproate in women of childbearing potential following completion 
of the RAF, with 25% reporting “all” WCP under their care continued valproate post-RAF (n= 50), (Figure 
2A). Ten percent of clinicians reported that valproate was stopped in “all” patients following review 
(n=20), (Figure 2A). Over 70% of clinicians reported that “all” or “most” of the WCP weaned off valproate 
were changed to a new medication (n=68, 37.8% and n=60, 33.3%, respectively), (Figure 2B). Lamotrigine 
and levetiracetam were most frequently used when valproate replaced, (Figure 2C).
Clinician estimated outcomes for WCP continuing valproate (n=167) were compared with those changed 
to levetiracetam (n=97) or lamotrigine (n=108) following the RAF (Figure 2D). Continuing valproate was 
associated with significantly better symptom control (seizure control in almost all cases) than changing to 
levetiracetam or lamotrigine. 48% (n=80) of clinicians reported that WCP continuing on valproate were 
“seizure free”, in contrast to 29% (n=28) and 20% (n=20) in patients changed to levetiracetam and 
lamotrigine, respectively (P<.05). 61% (n=102) of clinicians reported seizure rates to be “stable” amongst 
patients continuing valproate, in comparison to 49% (n=48) and 41% (n=44) on levetiracetam and 
lamotrigine, respectively. A deterioration in seizure control was reported more frequently by clinicians 
caring for WCP weaned off valproate and changed to levetiracetam (n=32, 33%) or lamotrigine (n=46, 
43%), than in those continuing valproate (7%) (P<.001). Clinician-reported status epilepticus in WCP was 
rare and similar across all three medications. There was one reported epilepsy-related death, occurring in 
a patient continuing valproate (n=1, 1%), (Figure 2D). 
Respondents reported 4-8% of patients experienced negative mood changes or other adverse events on 
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Outcomes following completion of RAF in WCP with intellectual disability (ID) taking Valproate
Similar patient outcomes were reported for WCP with ID following completion of the RAF (ID; 
Supplemental Figure 2). 80% (n=140) of clinicians surveyed stated that valproate was continued in “all” or 
“most” WCP with ID (Supplemental Figure 2A); comments indicate this was because it is “efficacious”, 
keeping seizure rates stable in WCP that are generally “not sexually active” and/or under carer 
supervision. 42.5% of clinicians reported that “all” or “most” of the 10% of WCP under their care weaned 
off valproate were changed to a new medication (n=57; Supplemental Figure 2B); usually to lamotrigine 
or levetiracetam (Supplemental Figure 2C). 
As reported by clinicians, continuing valproate was associated with more favourable epilepsy outcomes 
(seizure “free”, “rate stable” or “incidence reduced”) and “same” or “better” mood in WCP with ID 
compared to outcomes when changed to levetiracetam and lamotrigine; status epilepticus occurred in 
two patients switched to lamotrigine (4%, n=2). No pregnancies were reported in WCP with ID continuing 
valproate. Two pregnancies were reported in WCP with ID switched to levetiracetam or lamotrigine, 
(Supplemental Figure 2D). The outcome of these, and all pregnancies reported, is unknown.
Changes to contraception methods following completion of RAF in WCP 
47% of clinicians stated that “highly” efficacious” contraception (intrauterine device or depot injections) 
did not replace pre-existing pregnancy prevention in any WCP without ID post-RAF completion (n=87). In 
WCP with ID, 61% of clinicians reported that none of their patients switched to “highly efficacious” 
contraception (n=91). 19% of clinicians reported that “all” of their patients with ID or their carers declined 
“highly efficacious” contraception (n=28), in contrast to 9% for WCP without ID (n=17), (Supplemental 
Figure 3). 
Review of the Risk Acknowledgement Form
37% (n=80) of clinicians reported that patients were satisfied with the RAF, whilst 31% (n=66) reported 
patients were dissatisfied or strongly dissatisfied with the form, (Figure 3A). 40% (n=87) of clinicians were 
dissatisfied or strongly dissatisfied with the RAF, (Figure 3B). Clinician reported patient comments include 
that RAF is “time-consuming”, a “tick-box exercise”, “invasive”, “marginalizing” and “feels weighted 
towards the patient in terms of accountability”, (Table).
45% (n=97) of respondents “disagreed” or “strongly disagreed” that they had sufficient resources to 
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had sufficient resources to deal with filling in the RAF (n=57), (Figure 3C). 49% (n=106) of clinicians 
reported annotating the RAF document more than half the time (Supplemental Figure 4A). 13.5% (n=29) 
of those surveyed reported using and/or producing additional resources to aid in reviewing WCP on 
valproate, principally easy read information leaflets/booklets, (Supplemental Figure 4B).
[Table  about here]
DISCUSSION
Annual completion of the newly modified risk acknowledgement form (RAF) and enrolment in the 
pregnancy prevention programme (PPP) is now required for continued valproate prescription in the 
United Kingdom, and elsewhere. Patients must first be identified and reviewed.  There is no standard 
procedure for this. Almost half of respondents used a combination of modalities for this process (Figure 
1). Whilst manual record searches, pharmacy searches and appointments were most frequently used 
together, comments also indicate an increase in GP referrals and demands on outpatient clinics. 
Importantly, completion of the risk acknowledgement form is not universal amongst WCP on valproate; 
6% of respondents were unsure of their patients’ RAF completion status and only 43% stated the RAF had 
been completed in “all” of the WCP under their care (Figure 1). 
MHRA guidance mandating the enrolment of WCP taking valproate onto a pregnancy prevention 
programme is a consequence of the recognised risk of foetal teratogenicity and neurodevelopmental 
disorders with in utero exposure to valproate. Achieving adequate seizure control or symptom control is 
sometimes a difficult and dynamic balance. It is recognised that valproate may be the only medication 
that controls potentially dangerous symptoms, particularly for genetic generalised epilepsies. Clinicians 
reported that following completion of the risk acknowledgement form, the majority of WCP under their 
care continued valproate (68.5%, Figure 2). Many of these women had already tried or considered other 
medications that were ineffective. A recent survey in Poland had similar findings.[11]  
Clinicians reported that patients switched from valproate to another medication (usually lamotrigine or 
levetiracetam) had worse clinical outcomes, with significant deterioration in seizure control, including 
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study reporting clinical deterioration in 36/51 (70.6%) of WCP with idiopathic generalized epilepsy 
discontinuing VPA.[12] SANAD II showed superior effectiveness of valproate over levetiracetam in 
generalised and unclassifiable epilepsy in an un-blinded randomised controlled trial.[2]  A few clinicians 
reported restarting valproate following a change and deterioration of epilepsy control (despite previously 
being stable), however being unable to achieve the same seizure control. 
There were 14 pregnancies in total reported by clinicians occurring following completion of the RAF in this 
group; 5 in those continuing on valproate (none occurred in WCP with ID). Their outcome is as yet 
unknown. 
Responses suggest more clinicians than patients report dissatisfaction with the new process/form (40% 
versus 31% respectively, Figure 3). Some patients commented to their nurses and doctors that they were 
grateful to have time dedicated to explaining the risks associated with valproate and that such 
information should be delivered face to face, allowing patients to ask questions and explore their options. 
The majority of respondents leaving comments reported that patients were confused and often irritated 
by having to have an additional appointment to discuss risks that has already been explained to them 
prior to starting treatment especially when they are not permitted to decide about their treatment and 
methods of contraception/pregnancy prevention. Comments also highlight that the form fails to account 
for or make adjustment for individual circumstances such as severe ID, same-sex couples, hysterectomy 
or sterilisation. Some patients describe feeling offended and discriminated against. Recent modifications 
to the RAF will allow “opt out” of the PPP form when pregnancy is not considered possible and should 
reduce this problem.[13] 
Strengths and limitations of the study
This is the first survey of outcomes and views by professional users of the valproate RAF. A survey of 
patient views is underway. The key shortfall is that it does not capture the views of all prescribers, nor all 
females taking or considering valproate. Like all surveys, and the pregnancy registers, participants cannot 
be randomly selected. Neither the total number of specialist clinicians responsible for reviewing relevant 
patients and completing the RAF, nor the number of women of childbearing age taking valproate is 
known. There are no government measures in place to capture these data prospectively. The best way to 
do this is a nationwide or multi-nation study using data linkage. Despite this limitation, an estimated 4775 
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Policy implications
To prevent associated congenital malformations and developmental delay, the MHRA recommendations 
aim to prevent all pregnancies in women taking valproate. This survey found five reported pregnancies in 
women taking valproate, in comparison to nine in those weaned off valproate. 
The surveyed clinicians reported that changing from valproate to another medication worsened 
symptoms (more seizures in 33-43%, worse mood in 4-6%) of their patients.  Informed consent, the 
Montgomery ruling, and GMC requirements mandate full disclosure of risk.[14,15]  To align with these 
principles, the MHRA must add to the risk of worsening symptoms (for seizures is in the order of 30-40%) 
on changing from valproate to other medications to the patient information booklet and their websites. 
The risk of valproate to fetal development is at the forefront of the MHRA concerns. Women’s 
reproductive potential should not eclipse the impacts of incomplete seizure control on premature 
mortality and quality of life.
Unanswered questions and further research
The true impact of the changes in legislation and practice following the introduction of the valproate risk 
acknowledgement form and pregnancy prevention programme is unknown and there is no systematic 
gathering of this data.  The valproate RAF should be online, and all patient outcomes (seizure control, 
safety, mood, longitudinal effects on IQ and cognition of girls and women), as well as pregnancy-related 
outcomes, collected nationally and systematically. We have the technology and systems to do this. There 
should be provisions also for patient, carer and clinician feedback on the forms and the process. This 
information is essential for both patients and clinicians to inform current and future decision making.  
Data sharing statement 
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TABLES
.
Table. Clinician Comments on Risk Acknowledgement Form for Women of Childbearing Potential
“[the RAF] is heavy-handed and feels weighted towards the patient in terms of accountability.”
“Not designed for women who want to make an informed choice…Major issues with enforced contraception, 
consent in children, consent in learning disability, bodily autonomy in adults without LD and same sex couples.”
“It is useful to document VPA and WWE issues, however I am not sure that this form improves what I was doing 
before.”
“Most of the patients are willing to engage with this and grateful for the support. Those who are cross about the 
PPP are less likely to be satisfied and feel this is further marginalising them.”
“Significant increase in referrals and demands on outpatient appointments.”
“Not really appropriate for GP use and yet with long waits for neurology review we are the docs prescribing 
valproate.”
“No section to comment on individual circumstances.”
"For the women who are stable and well controlled they find it irritating that they know the risks but are not 
allowed to make informed decisions and are required to attend a hospital appointment.”
“Mandates annual forms, even if pregnancy is impossible e.g. hysterectomy or sterilisation which individual 
patients have found frustrating.”










This article is protected by copyright. All rights reserved
FIGURE LEGENDS 
Figure 1. Identification of WCP taking Valproate and RAF Completion Requires Combining Multiple Search 
Methods 
(A) Methods utilized by surveyed healthcare professionals to identify women of childbearing potential 
(WCP) taking valproate that require review and completion of risk acknowledgement form (RAF); orange 
bars indicate where combinations of methods have been used. (B) Diagrammatic representation of the 
proportion of WCP for which a RAF has been completed. N= number of responses. N=215, with 
approximately 4775 WCP on valproate under active care. 
Figure 2. Worse Clinical Outcomes Reported when Valproate was Discontinued Following Completion of 
the RAF in WCP without ID 
Diagrammatic representation of the proportion of patients (A) continued on valproate and the proportion 
(B) weaned off valproate and initiated on new medication after review and completion of the risk 
acknowledgement form (RAF) for women of childbearing potential without intellectual disability (ID). N= 
number of responses. N=200 and N=180 for Figures 2A and 2B, respectively. Medications used to replace 
valproate shown in (C). (D) Clinician estimated outcomes for patients continued on valproate (red, n=167), 
changed from valproate to levetiracetam (dark blue; n=97) or lamotrigine (light blue; n=108), with focus 
on seizure frequency and duration, epilepsy related death, mood and incidence of pregnancy. 
Figure 3. Clinicians Lack Confidence and Satisfaction with the RAF Process for WCP on Valproate 
Diagrammatic representation of (A) patient/carer and (B) clinician satisfaction with the risk 
acknowledgement form (RAF). N= number of clinicians surveyed; N=215. (C) Diagrammatic representation 
of confidence with completing the RAF; 215 healthcare professionals were asked to grade how strongly 
they agree with “`I have sufficient resources to deal with…” + various statements relating to the patient 
review and RAF completion process. The asterix indicates statements for which “neutral,” disagree” 
and/or “strongly disagree” responses outnumber “agree” responses.
Supplemental Figure 1. Diagnosis of Women of Childbearing Potential Taking Valproate
215 clinicians were asked to select all relevant diagnostic indications for valproate in the approximately 
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that epilepsy (purple), migraine (red), bipolar disease (yellow), other mood disorder (green), intellectual 
disability (ID; blue) was reported is shown, with overlapping areas indicating co-morbidities.
Supplemental Figure 2. Worse Clinical Outcomes Reported when Valproate Discontinued Following 
Completion of the RAF in WCP with ID
Diagrammatic representation of the proportion of patients (A) continued on valproate and the proportion 
(B) weaned off valproate and initiated on new medication after review and completion of the risk 
acknowledgement form (RAF) for women of childbearing potential with intellectual disability (ID). N= 
number of responses. N=175 and N=134 for Supplemental Figure 2A and 2B, respectively. Replacement 
medications following weaning of Valproate shown in (C). (D) Clinician estimated outcomes for patients 
continued on valproate (red; n= 132), changed from valproate to levetiracetam (dark blue; n=55) or 
lamotrigine (light blue; n=56), with focus on seizure frequency and duration, epilepsy related death, mood 
and incidence of pregnancy. 
Supplemental Figure 3. Completion of the RAF is not Associated with Increased Use of “Highly Efficacious” 
Contraception
Each clinician was asked to report the proportion of WCP taking valproate under their care in which:
(A-B) “highly efficacious” contraception (intrauterine device or depot injection) was continued post-RAF; 
diagrammatic representation of patients (A) without intellectual disability (n=191) and (B) with 
intellectual disability (n=156).
(C-D) “highly efficacious” contraception had replaced another pre-existing contraception; diagrammatic 
representation of patients (C) without intellectual disability (n=184) and (D) with intellectual disability 
(n=150).
(E-F) “highly efficacious” contraception has been declined; diagrammatic representation of patients (E) 
without intellectual disability (n=188) and (F) with intellectual disability (n=150)
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Supplemental Figure 4. Annotation to the RAF and Information Aids are Frequently Required when 
Reviewing WCP on Valproate  
Diagrammatic representation of (A) how frequently healthcare professionals annotated the RAF and (B) 
whether additional resources were used/produced to aid in reviewing women of childbearing potential on 
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